Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
CELC

CELC - Celcuity Inc Stock Price, Fair Value and News

15.01USD-0.33 (-2.15%)Market Closed

Market Summary

CELC
USD15.01-0.33
Market Closed
-2.15%

CELC Stock Price

View Fullscreen

CELC RSI Chart

CELC Valuation

Market Cap

479.1M

Price/Earnings (Trailing)

-6.52

EV/EBITDA

-6.6

Price/Free Cashflow

-8.23

MarketCap/EBT

-6.52

CELC Price/Sales (Trailing)

CELC Profitability

Return on Equity

-54.92%

Return on Assets

-39.03%

Free Cashflow Yield

-12.15%

CELC Fundamentals

CELC Earnings

Earnings (TTM)

-73.5M

Earnings Growth (Yr)

-81.03%

Earnings Growth (Qtr)

-14.66%

Breaking Down CELC Revenue

Last 7 days

7.0%

Last 30 days

-9.1%

Last 90 days

-13.5%

Trailing 12 Months

45.2%

How does CELC drawdown profile look like?

CELC Financial Health

Current Ratio

11.23

CELC Investor Care

Shares Dilution (1Y)

42.22%

Diluted EPS (TTM)

-2.78

Tracking the Latest Insider Buys and Sells of Celcuity Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 10, 2024
nigon richard
acquired
48,079
9.5
5,061
-
Jun 04, 2024
buller richard e
acquired
-
-
1,079
-
May 22, 2024
buller richard e
gifted
-
-
-1,958
-
May 22, 2024
buller richard e
gifted
-
-
1,958
-
Apr 26, 2024
sullivan brian f.
gifted
-
-
-45,025
chief executive officer
Apr 26, 2024
sullivan brian f.
gifted
-
-
45,025
chief executive officer
Apr 24, 2024
buller richard e
sold
-5,971
17.06
-350
-
Mar 18, 2024
sullivan brian f.
gifted
-
-
765,897
chief executive officer
Mar 18, 2024
sullivan brian f.
gifted
-
-
-765,897
chief executive officer
Feb 21, 2024
buller richard e
sold
-4,952
14.15
-350
-

1–10 of 50

Which funds bought or sold CELC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-36.04
-2,166
39,679
-%
May 16, 2024
JANE STREET GROUP, LLC
new
-
669,298
669,298
-%
May 15, 2024
STATE STREET CORP
added
13.44
2,946,970
7,269,260
-%
May 15, 2024
PERCEPTIVE ADVISORS LLC
added
59.47
29,442,700
51,025,200
0.89%
May 15, 2024
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.
sold off
-100
-874,200
-
-%
May 15, 2024
BAKER BROS. ADVISORS LP
added
189
25,731,600
33,533,500
0.42%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
new
-
1,928,340
1,928,340
-%
May 15, 2024
AMERIPRISE FINANCIAL INC
added
7.08
2,420,800
6,541,840
-%
May 15, 2024
VR Adviser, LLC
reduced
-48.56
-6,520,290
20,952,000
1.00%
May 15, 2024
MARSHALL WACE, LLP
new
-
2,350,400
2,350,400
-%

1–10 of 48

Are Funds Buying or Selling CELC?

Are funds buying CELC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CELC
No. of Funds

Unveiling Celcuity Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 10, 2024
biotechnology value fund l p
5.2%
1,828,267
SC 13G
Feb 14, 2024
commodore capital lp
9.9%
2,492,886
SC 13G/A
Feb 14, 2024
venrock healthcare capital partners iii, l.p.
9.99%
2,476,980
SC 13G/A
Feb 14, 2024
ra capital management, l.p.
5.0%
1,286,960
SC 13G/A
Feb 14, 2024
perceptive advisors llc
6.1%
1,481,300
SC 13G/A
Feb 12, 2024
morgan stanley
9.1%
2,195,026
SC 13G/A
Feb 09, 2024
soleus capital master fund, l.p.
9.9%
2,623,890
SC 13G/A
Feb 07, 2024
laing lance g.
5.5%
1,421,036
SC 13G/A
Feb 07, 2024
sullivan brian f.
14.0%
3,648,665
SC 13G/A
Dec 26, 2023
perceptive advisors llc
5.7%
1,441,300
SC 13G

Recent SEC filings of Celcuity Inc

View All Filings
Date Filed Form Type Document
Jun 12, 2024
4
Insider Trading
Jun 10, 2024
SC 13G
Major Ownership Report
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
May 31, 2024
8-K
Current Report
May 30, 2024
424B5
Prospectus Filed
May 30, 2024
8-K
Current Report

Peers (Alternatives to Celcuity Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
13.11% 15.14%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.19% -19.39%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
5.74% -10.79%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
9.90% 2.05%
18.71
3.7
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.86
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.06
56.43% 98.83%
2.0B
996.6M
11.65% 94.95%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
22.84% 567.64%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-17.34% 57.33%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Celcuity Inc News

Latest updates
MarketBeat12 Jun 202409:55 pm
Defense World03 Jun 202409:04 pm
MarketBeat01 Jun 202412:22 am
Seeking Alpha30 May 202411:53 am

Celcuity Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.6%18819114215416517665.0072.0080.0086.0092.0043.0036.0013.0015.0017.0018.0020.0022.0023.0025.00
  Current Assets-1.6%18819114215316417565.0072.0079.0085.0091.0042.0036.0012.0014.0016.0017.0019.0021.0022.0024.00
    Cash Equivalents1.8%31.0031.0026.0032.0034.0025.0057.0067.0078.0084.0090.0042.0035.0012.0014.0015.0017.0019.0016.0015.0015.00
  Net PPE33.8%0.000.000.000.000.000.000.000.000.000.000.000.000.001.001.001.001.001.001.001.001.00
Liabilities5.8%54.0051.0049.0043.0042.0042.0022.0019.0018.0017.0017.0016.001.001.001.001.001.001.001.001.001.00
  Current Liabilities17.7%17.0014.0013.007.006.007.007.004.004.003.003.002.001.001.001.001.001.001.001.001.001.00
Shareholder's Equity-4.3%13414093.0011012313444.0053.0062.0069.0074.0027.0035.0012.0014.0016.0018.0019.0021.0022.0024.00
  Retained Earnings-13.5%-181-160-141-122-108-96.30-84.72-73.82-63.86-55.93-49.17-43.15-29.11-26.32-23.77-21.30-19.09-16.85-15.04-13.05-11.33
  Additional Paid-In Capital5.2%31530023423323123012812712512512470.0064.0038.0038.0037.0037.0036.0036.0035.0035.00
Shares Outstanding20.7%31.0026.0022.0022.0022.0022.0015.0015.0015.0015.0015.0013.00---------
Float----191---96.00---198---41.00---146-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations7.9%-17,068-18,535-12,746-9,662-12,867-9,479-9,306-11,289-5,933-6,124-4,048-7,617-2,521-2,107-1,648-1,556-1,833-1,703-1,478-1,226-1,590
  Share Based Compensation7.1%1,3311,2431,1091,2771,2731,1391,2231,519756921700540449427449423465361303192185
Cashflow From Investing108.6%3,536-41,2186,2528,09021,868-143,985-12.10-22.99-11.63-9.94-14.06-26.97-30.42-13.88-8.90-20.98-45.604,1372,8311,364197
Cashflow From Financing-78.2%14,08464,65715.0017268.00120,552-108-72.52-46.2954.0052,79114,34625,85163.00-76.47153-1.4432.00-1.4357.00172
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CELC Income Statement

2024-03-31
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 20,647,559$ 11,278,493
General and administrative1,846,2761,269,044
Total operating expenses22,493,83512,547,537
Loss from operations(22,493,835)(12,547,537)
Other income (expense)  
Interest expense(1,400,712)(1,242,012)
Interest income2,282,0921,851,132
Other income, net881,380609,120
Net loss before income taxes(21,612,455)(11,938,417)
Income tax benefits
Net loss$ (21,612,455)$ (11,938,417)
Net loss per share, basic$ (0.64)$ (0.55)
Net loss per share, diluted$ (0.64)$ (0.55)
Weighted average common shares outstanding, basic33,612,05421,680,877
Weighted average common shares outstanding, diluted33,612,05421,680,877

CELC Balance Sheet

2024-03-31
Condensed Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current Assets:  
Cash and cash equivalents$ 31,214,741$ 30,662,774
Investments146,447,843149,919,974
Other current assets9,860,53510,007,849
Total current assets187,523,119190,590,597
Property and equipment, net306,024228,782
Operating lease right-of-use assets351,911400,019
Total Assets188,181,054191,219,398
Current Liabilities:  
Accounts payable5,276,6905,076,699
Operating lease liabilities181,882184,950
Accrued expenses11,237,5098,927,094
Total current liabilities16,696,08114,188,743
Operating lease liabilities182,079225,922
Note payable, non-current37,566,23037,035,411
Total Liabilities54,444,39051,450,076
Commitments and Contingencies (Note 5)
Stockholders’ Equity:  
Preferred stock, $0.001 par value: 2,500,000 shares authorized; 505,277 and 854,134 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively505854
Common stock, $0.001 par value: 65,000,000 shares authorized; 30,773,895 and 25,506,012 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively30,77425,506
Additional paid-in capital315,393,843299,818,965
Accumulated deficit(181,688,458)(160,076,003)
Total Stockholders’ Equity133,736,664139,769,322
Total Liabilities and Stockholders’ Equity$ 188,181,054$ 191,219,398
CELC
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
 CEO
 WEBSITEcelcuity.com
 INDUSTRYBiotechnology
 EMPLOYEES45

Celcuity Inc Frequently Asked Questions


What is the ticker symbol for Celcuity Inc? What does CELC stand for in stocks?

CELC is the stock ticker symbol of Celcuity Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Celcuity Inc (CELC)?

As of Thu Jun 13 2024, market cap of Celcuity Inc is 479.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CELC stock?

You can check CELC's fair value in chart for subscribers.

What is the fair value of CELC stock?

You can check CELC's fair value in chart for subscribers. The fair value of Celcuity Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Celcuity Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CELC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Celcuity Inc a good stock to buy?

The fair value guage provides a quick view whether CELC is over valued or under valued. Whether Celcuity Inc is cheap or expensive depends on the assumptions which impact Celcuity Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CELC.